ArticleBioinformatics (Oxford, England)2025
esMPRA: an easy-to-use systematic pipeline for MPRA experiment quality control and data analysis.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uniform processing and analysis of IGVF massively parallel reporter assay data with MPRAsnakeflow.Genome research · 2026Article
- Uniform processing and analysis of IGVF massively parallel reporter assay data with MPRAsnakeflow.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationMassively Parallel Reporter Assays (MPRAs) have emerged as pivotal tools for systematically profiling cis-regulatory element activity, playing critical roles in deciphering gene regulation mechanisms and synthetic regulatory element engineering. However, MPRA experiments involve multi-step library processing procedures coupled with high-throughput sequencing. Operational errors during these complex workflows can lead to substantial resource depletion and experimental delays. Thus robust and user-friendly quality control methods are essential to minimize experimental failures and ensure reproducibility between replicates.
resultsHere, we present esMPRA, an integrated quality control and analysis pipeline designed for MPRA experiments. Building on our experience in MPRA and its derivative techniques, coupled with systematic analysis of public MPRA datasets, we established standardized quality control metrics and developed a stepwise quality monitoring framework. esMPRA generates stage-specific diagnostic reports and provides experimental recommendations to avoid potential risks throughout the workflow. Designed for maximal accessibility, esMPRA features a one-line command-line interface and requires minimal bioinformatics expertise. Beyond quality assessment, the pipeline delivers processed data outputs, comprehensive analysis reports, and interface files compatible with downstream analyses, establishing an end-to-end solution for MPRA experimentation. AVAILABILITY AND IMPLEMENTATION: esMPRA is released as an open-source software under the MIT license. The source code for esMPRA is available on Zenodo (DOI: 10.5281/zenodo.15362711) and GitHub (https://github.com/WangLabTHU/esMPRA/) for Linux, macOS, and Windows and is available via PyPI as esMPRA. Data for testing and reference is available via Zenodo repository at https://zenodo.org/records/15034449.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.